Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefapixant in Obstructive Sleep Apnea
NCT03882801Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of gefapixant in obstructive sleep apnea (OSA) (2 arms), sponsored by Merck & Co. Primary endpoint: Apnea-Hypopnea Index Change From Baseline at Day 7. Started Apr 2019; status: completed.
02
Drugs
gefapixant
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT03882801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03882801.